MERTK inhibitors have been confirmed to be used in combination with radiotherapy or chemotherapy in glioma, NSCLC, head and neck squamous cell carcinoma, and other tumors to achieve better efficacy [30–32]. Here, MERTK is linked to head and neck squamous cell carcinoma.